Navigation Links
Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
Date:8/29/2007

BOCA RATON, Fla., Aug. 29 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, initiated research coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy rating and a 12-18 month price target of $6.00. John M. Putnam, Sr. VP-Medical Devices, issued the report.

The report describes CryoCor's recently FDA-approved cryoablation system for atrial flutter and their current pivotal trial for atrial fibrillation. Mr. Putnam states "With the FDA's approval of CryoCor's cryoablation system for the treatment of atrial flutter, and the strong prospect of an approval for treating the much larger indication of atrial fibrillation in 2008, we believe the company is on the verge of meaningful revenue generation."

A copy of the report may be obtained by contacting Dawson James Securities at 561-391-5555.

About Dawson James Securities:

Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.DawsonJames.com

Disclosures:

Dawson James has not acted as an investment banker for the company mentioned in this report in the past, although Dawson James may have sought in the past, or may actively seek in the future, compensation for investment banking services. Dawson James and/or its directors and employees may own securities in the companies and may increase or decrease holdings in the future.

The analyst certifies that 1) all of the views expressed accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst; 3) the analyst responsible for preparing this research report receives compensation based upon various factors, including total revenues of Dawson James and its affiliates, a portion of which is generated by investment banking activities and 4) the analyst and/or members of their immediate family do not own stock in the companies mentioned.

Contact:

Dawson James Securities

John M. Putnam, 561-208-2950

Fax: 561-391-5757

Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 130645.


'/>"/>
SOURCE Dawson James Securities
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. State puts up $1 million for James Thomsons new stem cell startup
3. OpGen adds Thomas Pyle and James Ogle to board of directors
4. UW stem-cell team led by James Thomson gets $1.25M private grant
5. James Thomson plans to stay in Madison to study genesis of stem cells
6. Early Stage, Step 9: Raising capital in the securities landscape
7. Securities compliance is part of raising capital
8. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
9. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
10. Control Your siRNA Research
11. Getting Started with MicroRNA Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):